Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

29.94 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗

June 03, 2026

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Via The Motley Fool

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗

June 02, 2026

An upcoming trial result could change how investors think about the weight-loss drug market.

Via The Motley Fool

The Smartest Growth Stocks to Buy With $2,000 Right Now ↗

May 30, 2026

Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.

Via The Motley Fool

Topics Artificial Intelligence

Viking Therapeutics (NASDAQ:VKTX) Stock Holds Steady After Q1 2026 Earnings Miss on Higher Phase 3 Spending ↗

April 29, 2026

Via Chartmill

Topics Earnings

Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗

May 26, 2026

These players are seeing exciting results in clinical trials.

Via The Motley Fool

Don't Buy Viking Therapeutics Stock Until You Read This ↗

May 25, 2026

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

Via The Motley Fool

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗

May 25, 2026

The pharma giant is taking steps to expand its portfolio.

Via The Motley Fool

Is Viking Therapeutics a Top Takeover Target? ↗

May 23, 2026

Viking's strong obesity drug data continues fueling acquisition speculation.

Via The Motley Fool

2 Stocks That Could Realistically Double by 2030 ↗

May 22, 2026

Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead.

Via The Motley Fool

Could Viking Therapeutics Be the Next Eli Lilly? ↗

May 21, 2026

Demand for weight loss drugs may fuel growth for more than one player.

Via The Motley Fool

Best Weight Loss Drug Stocks to Buy in 2026 ↗

May 20, 2026

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Via The Motley Fool

Topics Intellectual Property

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗

May 18, 2026

This dark horse in the weight loss drug race is worth keeping on your watch list.

Via The Motley Fool

Eli Lilly Stock: Next Stop $2,000? ↗

May 18, 2026

The company is riding an incredible tailwind.

Via The Motley Fool

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗

May 14, 2026

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Via The Motley Fool

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

Via Investor Brand Network

InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

May 13, 2026

Via Investor Brand Network

Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months ↗

May 04, 2026

The Street is bullish on this biotech's prospects, but is the sentiment justified?

Via The Motley Fool

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

From BioMedWire

Via GlobeNewswire

Eli Lilly Just Announced Fantastic News for Shareholders ↗

May 04, 2026

Lilly's weight loss drugs have been delivering blockbuster revenue.

Via The Motley Fool

Topics Earnings

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗

May 01, 2026

Via MarketBeat

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗

April 30, 2026

This particular player has seen its yield rise in recent years.

Via The Motley Fool

This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗

April 26, 2026

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.

Via The Motley Fool

Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗

April 25, 2026

The weight loss drug market may reach almost $100 billion in a few years.

Via The Motley Fool

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

April 23, 2026

From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met

From Equity Insider

Via GlobeNewswire

Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗

April 17, 2026

One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.

Via The Motley Fool

Topics Artificial Intelligence

Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗

April 17, 2026

The stock could have plenty of room to run from current levels.

Via The Motley Fool

Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗

April 04, 2026

The answer to the question might surprise many investors. It pays to be open-minded about risk.

Via The Motley Fool

Topics Economy Energy

Where Will Viking Therapeutics Stock Be in 10 Years? ↗

April 03, 2026

There is a wide range of possibilities.

Via The Motley Fool

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

April 03, 2026

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...

Via MarketMinute

Topics Intellectual Property

Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring

April 02, 2026

Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require...

Via MarketMinute

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.